Ipca Laboratories shareholders approve all resolutions at 76th AGM
Ipca Laboratories shareholders approved all six resolutions at the 76th AGM on August 13, 2026. Key outcomes included the adoption of FY26 financials, dividend declaration, and re-appointments of directors Ajit Kumar Jain, Pranay Godha, and Prashant Godha. While promoter support was unanimous, the re-appointment of Executive Director Prashant Godha faced notable dissent from public institutional holders, who voted against it at a rate of 19.25%. The cost auditor remuneration was also ratified.
*this image is generated using AI for illustrative purposes only.
Shareholders of Ipca Laboratories approved all resolutions placed before them at the company’s 76th annual general meeting (AGM) held on August 13, 2026. The meeting, conducted via video conferencing and remote e-voting, saw the passage of ordinary resolutions regarding financial statements, dividends, and board appointments.
A total of 85,465 shareholders were on record as of the cut-off date, August 7, 2026. Of these, 57 shareholders attended the meeting through video conferencing, comprising 10 from the promoter group and 47 public shareholders. No shareholders were present in person or through proxy.
Voting Results Overview
The promoters, holding 113,467,472 shares, voted in favor of all resolutions. Public institutional holders, with 121,367,491 shares, also largely supported the agenda items, while public others held 18,869,255 shares.
| Resolution | Promoter Votes In Favor | Public Institutional Votes In Favor | Total Votes Polled | % In Favor |
|---|---|---|---|---|
| Adoption of Financial Statements (FY26) | 113,467,472 | 116,489,560 | 230,284,613 | 99.98% |
| Dividend Declaration | 113,467,472 | 116,549,044 | 230,303,593 | 99.99% |
| Re-appointment of Ajit Kumar Jain | 113,467,472 | 115,201,064 | 230,303,393 | 99.41% |
| Re-appointment of Pranay Godha | 113,467,472 | 115,284,003 | 230,303,393 | 99.45% |
| Re-appointment of Prashant Godha | 113,467,472 | 94,108,914 | 230,303,593 | 90.26% |
| Cost Auditor Remuneration | 113,467,472 | 116,549,044 | 230,303,593 | 99.99% |
Key Resolutions Passed
The first resolution involved the adoption of the audited financial statements for the financial year ended March 31, 2026, along with the reports of the Board of Directors and Auditors. This resolution received 99.98% of the votes polled in its favor.
The second resolution authorized the declaration of a dividend on equity shares. It was approved with 99.99% of the votes cast in favor. The promoter group voted unanimously for this resolution, as did nearly all public institutional holders.
Board Appointments
The AGM saw the re-appointment of three directors:
- Ajit Kumar Jain (DIN 00012657): Re-appointed as a Director. The resolution passed with 99.41% approval. Public institutional holders showed slight dissent, with 1,347,980 votes against.
- Pranay Godha (DIN 00016525): Re-appointed as a Director. The resolution secured 99.45% approval. Similar to Mr. Jain’s re-appointment, some institutional dissent was recorded.
- Prashant Godha (DIN 00012759): Re-appointed as Executive Director for a further period of five years commencing August 16, 2026. This resolution received the lowest support among the agenda items, with 90.26% of votes in favor. Notably, public institutional holders cast 22,440,130 votes against this resolution, representing 19.25% of their polled votes.
Other Matters
The final resolution ratified the remuneration payable to M/s. ABK & Associates, Cost Accountants (Firm Registration No. 000036), for conducting the cost audit for FY27. This proposal was approved with 99.99% of the votes polled.
Ms. Jigyasa N. Ved of M/s. Parikh & Associates served as the scrutinizer for the AGM. The e-voting facility was provided by National Securities Depository Limited (NSDL), with the voting period running from August 10 to August 12, 2026.
Historical Stock Returns for IPCA Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.12% | +0.63% | +16.77% | +32.01% | +49.92% | 0.0% |
What specific concerns led to the 19.25% institutional dissent against Prashant Godha's re-appointment, and will this impact his strategic decision-making authority?
How does the approved dividend payout ratio align with Ipca Laboratories' capital allocation strategy for upcoming R&D investments or debt reduction?
Will the re-appointment of the current board composition influence the company's approach to navigating potential regulatory changes in key export markets like the US and Europe?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
